buprenorphine

Quick answers

What is buprenorphine?

Buprenorphine (brand Subutex; generics) is a partial opioid agonist used to treat opioid use disorder (OUD). It can reduce withdrawal symptoms and cravings and is intended to be used as part of a comprehensive treatment plan with counseling and psychosocial support (label/guideline).

What is Subutex?

Subutex is a brand name for buprenorphine.

What is Subutex (buprenorphine) used for?

Label indications include: Opioid use disorder treatment (induction; selected maintenance scenarios) (label).

What drug class is Subutex (buprenorphine)?

Opioid Partial Agonist.

What is the mechanism of action of Subutex (buprenorphine)?

Partial μ-opioid receptor agonist used for opioid use disorder (OUD) treatment; reduces withdrawal and cravings and is commonly used for induction, with transition to buprenorphine/naloxone preferred for unsupervised maintenance when appropriate (label/guideline).

What strengths does Subutex (buprenorphine) come in?

Sublingual tablets (label): buprenorphine 2 mg and 8 mg.

General information

The buprenorphine monoproduct is commonly used for induction and for selected maintenance scenarios when naloxone-containing formulations are not tolerated. For many stable patients in outpatient care, the buprenorphine/naloxone combination is preferred for unsupervised maintenance (label/clinical).

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

• Partial μ-opioid receptor agonism with high receptor affinity (label).

Metabolism & pharmacokinetics

• Buprenorphine undergoes N-dealkylation to norbuprenorphine (primarily via CYP3A4) and glucuronidation; both buprenorphine and norbuprenorphine have conjugated metabolites (label).
• A mass balance study recovered radiolabel largely in feces (~69%) and urine (~30%) over 11 days, reflecting extensive metabolism and mixed renal/fecal elimination pathways (label).
• After sublingual administration, the label reports a mean elimination half-life range of ~31 to 35 hours (label).
• Buprenorphine is highly protein bound (~96%). Moderate-to-severe hepatic impairment can increase exposure and prolong half-life, so dosing and monitoring are often adjusted (label/clinical).

Dosing & administration

• Buprenorphine sublingual tablets are administered sublingually as a single daily dose (label).
• For short-acting opioids, the label recommends administering the first dose only when objective and clear signs of moderate opioid withdrawal are present and not less than 4 hours after the last opioid use (label).
• During induction, dosing may be given in 2 mg to 4 mg increments based on symptoms, with the goal of achieving an adequate dose as rapidly as possible while maintaining safety (label/clinical).
• After induction and stabilization, the label describes a maintenance dose range of 4 mg to 24 mg buprenorphine per day, with a target dosage of 16 mg once daily; doses above 24 mg have not shown additional clinical advantage (label).
• When transitioning from methadone, labeling notes higher precipitated withdrawal risk at higher methadone doses (>30 mg) and when the first buprenorphine dose is given shortly after the last methadone dose; plans are often individualized, particularly when fentanyl exposure is present (label/clinical).

Monitoring & labs

• Confirm objective withdrawal prior to induction to reduce precipitated withdrawal risk; document the induction plan and follow-up schedule (label/clinical).
• Monitor sedation and respiratory risk, especially when alcohol, benzodiazepines, or other sedatives are present; opioid overdose education and naloxone access planning are common (label/clinical).
• Track cravings, ongoing opioid use, and functional outcomes; adjust the treatment plan if goals are not being achieved (label/clinical).
• Monitor for oral/dental adverse effects and reinforce rinsing/oral hygiene practices recommended in labeling (label/clinical).

Follow-up intensity is commonly individualized based on stability, safety, and diversion risk, especially during early treatment (label/clinical).

Adverse effects

Interactions

• CNS depressants (benzodiazepines, alcohol, sedatives) can increase the risk of respiratory depression when combined with buprenorphine (label/clinical).
• CYP3A4 inhibitors may increase buprenorphine levels and CYP3A4 inducers may reduce levels, affecting withdrawal control and opioid effects; regimen review matters when strong inhibitors/inducers are present (label/clinical).
• Buprenorphine’s receptor affinity can reduce the efficacy of full opioid agonists for analgesia; perioperative and acute pain management often requires proactive planning (clinical).

Other useful information

• Evidence syntheses support buprenorphine maintenance for improving retention and reducing illicit opioid use compared with placebo/no medication, with methadone often showing higher retention at adequate doses (review).
• Guidelines emphasize that medication for opioid use disorder (MOUD) is typically long-term and is most effective when paired with follow-up, psychosocial supports, and harm-reduction planning (guideline/clinical).
• In psychiatric practice, common co-occurring issues include anxiety, insomnia, trauma, and co-prescribed sedatives; integrated care often focuses on minimizing sedative stacking and monitoring respiratory risk (clinical).

References